Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Program onkologického rodičovství pro zlepšení kvality života pacientů s pokročilou rakovinou a jejich dětí (EC-PC)

25. srpna 2026 aktualizováno: Frances M. Lewis, University of Washington

Posílení spojení – paliativní péče: Program rodičovství s rakovinou pro pacienty s pokročilou rakovinou a jejich děti

This trial examines the usefulness of two educational programs for parents with late-stage cancer who have a 5 - 17 year old child. The programs are designed to enhance the quality of the parent-child relationship and add to the parent's confidence in managing the impact of their cancer on their child. Educational programs may reduce anxiety and depression and improve the well-being and quality of life of parents with advanced cancers and their children.

Recruitment occurs nationally via referral to the Fred Hutch/University of Washington Cancer Consortium team.

Přehled studie

Postavení

Ukončeno

Podmínky

Intervence / Léčba

Detailní popis

OUTLINE: Patients are randomized to 1 of 2 groups. Co-inhabiting non-ill parent or parent surrogate is also randomized with the patient but only the patient receives either the experimental or control group information.

GROUP I (ENHANCING CONNECTIONS-PALLIATIVE CARE [EC-PC] PROGRAM): Patients receive the 5-session EC-PC program bi-weekly with a patient educator about ways to help them talk to and support their child.

Group I had 2 arms: Arm 1: Ill parents Arm 2: Non-ill parents. The enrolled non-ill parent did not provide data to evaluate the efficacy of the trial.

GROUP II (CONTROL): Patients receive carefully selected educational booklet that discuss ways to talk about their cancer with their child and a scripted phone call from a trained phone counselor on study.

Group II had 2 arms: Arm 1: Ill parents Arm 2: Non-ill parents. The enrolled non-ill parent did not provide data to evaluate the efficacy of the trial.

Typ studie

Intervenční

Zápis (Aktuální)

174

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • District of Columbia
      • Washington D.C., District of Columbia, Spojené státy, 20007
        • Georgetown University
    • Washington
      • Seattle, Washington, Spojené státy, 98115
        • Fred Hutch/University of Washington Cancer Consortium

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

23 let až 68 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Parents with any type of late-stage, non-curable cancer (determined by TNM stage IV cancer for solid tumors or 2 or more cycles of treatment failure with disease relapse in non-solid tumors)
  • All therapies are allowable
  • 23 years (yr.) to 68 yr. Age restriction exists for the patient based on parent having a child ages 5-17
  • Patient must have a child (5yr. -17 yr.) living in the home at least 50% of the time and residential with non-ill parent or parent surrogate
  • Read and write English as one of their languages of choice
  • Have access to a telephone
  • Ability to understand and the willingness to sign a written informed consent document. Read and write English as one of their languages of choice

Exclusion Criteria:

  • Patient is in hospice at time of enrollment
  • Non-ill co-parent does not consent to join study

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Podpůrná péče
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Trojnásobný

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Behavioral: Group 1: Educational counseling Group I (enhancing connections-palliative care program)

Patients receive the 5-session EC-PC program bi-weekly with a patient educator about ways to help them talk to and support their child.

Enrolled parents received 5 telephone-delivered educational counseling interventions at 2-week intervals, the EC-PC Program.

Ostatní jména:
  • EC-PC
Aktivní komparátor: Group II (educational material)

Patients receive carefully selected educational booklet that discuss ways to talk about their cancer with their child and a scripted phone call from a trained phone counselor on study.

Patients receive carefully selected educational booklet that discuss ways to talk about their cancer with their child and a scripted phone call from a trained phone counselor on study.

Ostatní jména:
  • Kontrolní skupina

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Treatment Efficacy Assessed by Parents' Mood-Center for Epidemiological Studies-Depression (CES-D)
Časové okno: At 3 months post-baseline

Depressed mood will be measured by the 20-item Center for Epidemiological Studies- Depression Scale (CES-D) (Radloff, 1977). The CES-D Scale measures the recent occurrence of symptoms of depression. For each symptom, the respondent indicates the frequency with which that symptom has occurred during the past week, from "rarely or none of the time (less than 1 day)" to "most or all of the time (5-7 days)." This measure has been well- accepted in both ill and non-ill samples. Internal consistency in three samples from the general population has been reported by Radloff, 1977, and ranged between .84 to .85. Validity is well- established, including its link to the broader concept of "distress" in cancer-related research (Benazon & Coyne, 2000). The internal consistency reliability is 0.85 or higher (Benazon & Coyne, 2000). Total score ranges from 0-60. Higher scores denote worse outcome. Clinical cut off for distress is 16 or higher.

At 3 months post-baseline
Treatment Efficacy Assessed by Parents' Anxiety [Spielberger State-Trait Anxiety (STAI, State Scale)]
Časové okno: At 3 months post-baseline

State anxiety will be measured by the state component of the State-Trait Anxiety Inventory. This 20-item self-report questionnaire evaluates current feelings of apprehension, tension, nervousness, and worry. The respondent circles a response that best depicts their current feelings best. Response options range from [1 - Not at all] to [5 - Very much so]. Sample items include "I feel calm", I am tense." Higher scores denote greater anxiety. Internal consistency reliability is 0.90 or above in community and population samples [Edwards and Clarke, 2004]. Scale range: 20-80. Clinical cut off for distress is 40 or higher. Missing data imputation caused scores to be non-whole integers.

At 3 months post-baseline
Parent's Confidence in Being Able to Talk With Her Child About the Child's Cancer-related Concerns (CASE Help Child Subscale)
Časové okno: At 3 months post-baseline

Parenting Self-efficacy: Measured by the Help Child subscale of the parent-reported cancer Self-efficacy Scale (CASE). The Help Child subscale (9 items) measures the parent's confidence in being able to talk with her child about the child's cancer-related concerns; e.g., "I can assist my child to talk out his/her worries about my cancer." Structured response options range from "Not at all confident" (1) to "Very confident." The internal consistency reliability The internal consistency reliabilities in the EC seminal trial with parents with early stage cancer was 0.97. Higher scores denote better outcome. Range of scores: 0-90. There is no known clinical cutoff score on this measure.

At 3 months post-baseline
Parents' Skills in Helping Their Child Cope and Manage the Toll of the Parents' Cancer (Connecting and Coping Subscale)
Časové okno: At 3 months post-baseline

Parenting skills will be measured by the parent reported Parenting Skills Checklist: Connecting and Coping subscale developed by the study team and tested for reliability and validity in a 6-state randomized control trial (Lewis et al., 2015). The measure describes the observable interactional behaviors parents can use to assist their child disclose, discuss, and cope with the parent's cancer. The developmental-contextual model of parenting was the conceptual basis for the measure. An example item on the Connecting and Coping subscale includes, "I work with my child to help my child manage the child's stress related to my cancer." Range of subscale: 0-50. Higher scores reflect a better outcome. There is no clinical cut off score for parents' skills.

At 3 months post-baseline
Child-Behavioral Emotional Functioning: Anxious/Depressed Score on the Child Behavioral Checklist (CBCL)
Časové okno: At 3 months post-baseline

The child's behavioral-emotional adjustment will be measured by 3 subscales: the Anxious/Depressed scores, Internalizing Problems score, and Externalizing Problems scores, all part of the Child Behavior Checklist. See specific subscale scores, entered separately below. Response options for all subscales range from 0 to 2 from "Not True (as far as you know)" to "Somewhat or Sometimes True" to "Very True or Often True." Higher scores denote worse outcomes. Range of scores for Internalizing and Externalizing Problems is 34-100 and 50-100 for the Anxious/Depressed score. Internal consistency reliabilities were established as 0.90 for the Internalizing score and 0.94 for the Externalizing score. For the current study, the CBCL form for 6-18 year-olds and its computer software were used. The theoretical range of scores on the Anxious/Depressed score is 50-100. The theoretical range of the Internalizing and Externalizing problems subscales are both 34-100.

At 3 months post-baseline

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Condensed Memorial Symptom Assessment Scale (CMSAS) - Psychological Symptoms Subscale
Časové okno: At 3-months post-baseline

Self-report quantitative scale of patient's reported symptoms. BUT this was assessed as a potential covariate in the efficacy analysis and was used as such. It is not a primary nor a secondary outcome. Scores range from 0-4 with higher scores denoting greater psychological symptoms. There is no known clinical cut off score.

At 3-months post-baseline

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Spolupracovníci

Vyšetřovatelé

  • Vrchní vyšetřovatel: Frances M Lewis, RN, MN, PhD, University of Washington

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

19. července 2022

Primární dokončení (Aktuální)

21. května 2025

Dokončení studie (Aktuální)

15. srpna 2025

Termíny zápisu do studia

První předloženo

19. července 2022

První předloženo, které splnilo kritéria kontroly kvality

25. července 2022

První zveřejněno (Aktuální)

28. července 2022

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

22. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

25. srpna 2026

Naposledy ověřeno

1. srpna 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • RG1122669
  • R01NR019987-01A1 (Grant/smlouva NIH USA)
  • STUDY00011221 (Jiný identifikátor: Fred Hutch/University of Washington Cancer Consortium)
  • NCI-2022-08714 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

Secondary analysis of data will be permitted after a specific plan is submitted to the Principal Investigator and Co-Investigators approve.

Plan should make explicit the analysis sample, rationale for study, aims of secondary analysis, proposed data analysis to be used, timeline for completion of analysis, and agreement to cite the parent study with appropriate acknowledgment.

Časový rámec sdílení IPD

Data will become available after filing FINAL Report to NINR, NIH and after the efficacy results and analysis of study aims are published.

Kritéria přístupu pro sdílení IPD

Scientists prepared with a PhD or equivalent degree will be granted access for secondary analysis, after their specific proposed plan is submitted and reviewed by PI and Co-Invesigators.

Typ podpůrných informací pro sdílení IPD

  • PROTOKOL STUDY
  • MÍZA
  • ICF
  • CSR

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .